Literature DB >> 21725255

Can we predict the efficacy of the semont maneuver in the treatment of benign paroxysmal positional vertigo of the posterior semicircular canal?

Andrés Soto-Varela1, Marcos Rossi-Izquierdo, Sofía Santos-Pérez.   

Abstract

OBJECTIVE: To establish success- or failure-predicting factors in Semont maneuver in the treatment of benign paroxysmal positional vertigo. STUDY
DESIGN: Prospective study.
SETTING: Referral center, institutional practice, ambulatory care (outpatient clinic). PATIENTS: A consecutive sample of 135 patients diagnosed with unilateral benign paroxysmal positional vertigo of posterior semicircular canal for 3 years (September 2007 to August 2010). INTERVENTION: Semont maneuver. MAIN OUTCOME MEASURES: Duration of the latency period and nystagmus status with the Dix-Hallpike test. Presence or absence of orthotropic nystagmus in the second position of the Semont maneuver. Effectiveness of the Semont maneuver (cure versus no cure).
RESULTS: The Semont maneuver is effective in 73% of the patients. Orthotropic nystagmus was present in 67% of the cases and absent in 33%; when we found orthotropic nystagmus, the maneuver was effective in 81% of the patients, but only in 57% if this nystagmus was not present (Fisher's exact test, p = 0.004; odds ratio, 3.308; 95% confidence interval, 1.492-7.334). The maneuver's efficacy and the presence of orthotropic nystagmus were not affected by the duration of nystagmus status in the Dix-Hallpike test. The duration of the latency period had no effect on the maneuver's efficacy, but it did affect the appearance of orthotropic nystagmus (Mann-Whitney test, p = 0.016).
CONCLUSION: The presence of orthotropic nystagmus in the second position of the Semont maneuver indicates a good prognosis, but its absence does not necessarily mean that the maneuver will fail. Orthotropic nystagmus is more common in patients with shorter latency periods, suggesting that its appearance is related to cupulolithiasis mechanisms.

Entities:  

Mesh:

Year:  2011        PMID: 21725255     DOI: 10.1097/MAO.0b013e3182267f02

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  6 in total

1.  Double-blind randomized trial on short-term efficacy of the Semont maneuver for the treatment of posterior canal benign paroxysmal positional vertigo.

Authors:  Marco Mandalà; Giovanni Paolo Santoro; Giacinto Asprella Libonati; Augusto Pietro Casani; Mario Faralli; Beatrice Giannoni; Mauro Gufoni; Vincenzo Marcelli; Pierpaolo Marchetti; Emanuela Pepponi; Paolo Vannucchi; Daniele Nuti
Journal:  J Neurol       Date:  2011-10-19       Impact factor: 4.849

2.  Analysis of risk factors influencing the outcome of the Epley maneuver.

Authors:  E Domínguez-Durán; E Domènech-Vadillo; M G Álvarez-Morujo de Sande; R González-Aguado; G Guerra-Jiménez; Á Ramos-Macías; C Morales-Angulo; A J Martín-Mateos; E Figuerola-Massana; H Galera-Ruiz
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-07-19       Impact factor: 2.503

3.  Vertigo during the Epley maneuver and success rate in patients with BPPV.

Authors:  Georgios Fyrmpas; Eustathios Barkoulas; Anna Bettina Haidich; Miltiadis Tsalighopoulos
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-12-01       Impact factor: 2.503

4.  Vertigo returning to the sitting position after the Semont manoeuvre. Is it a prognostic symptom?

Authors:  A Albera; M Boldreghini; A Canale; R Albera; C F Gervasio
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-04       Impact factor: 2.124

Review 5.  Treatment of benign paroxysmal positional vertigo. A clinical review.

Authors:  Paz Pérez-Vázquez; Virginia Franco-Gutiérrez
Journal:  J Otol       Date:  2017-08-25

6.  Association between Dix-Hallpike test parameters and successful repositioning maneuver in posterior semicircular canal benign paroxysmal positional vertigo: a case-control study.

Authors:  Jia Yu; Guilin Meng; Shaofang Xu; Pengfei Chen; Xiaoqing Liu; Yanxin Zhao; Xueyuan Liu; Aiping Jin
Journal:  Ann Transl Med       Date:  2020-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.